SLC5A2 and diabetic kidney disease: Notably, several clinical trials have demonstrated that SGLT2 inhibitors may provide cardiovascular and renal benefits to patients with DKD in the form of a lower estimated GFR, a reduced risk of ESRD, and a lower rate of mortality due to cardiovascular effects 185-187.